Skip to main content

Advertisement

Table 2 Treatment and clinical outcomes of EIB and TB-AOI cases - Alberta, 2004–14

From: Program-wide review and follow-up of erythema Induratum of Bazin and tuberculosis-associated ocular inflammation management in a TB low-incidence setting: need for improved treatment candidate selection, therapy standardization, and care collaboration

  EIB (n = 21) TB-AOI (n = 20)
Type of treatment
 Directly observed 13 5
 Self-administered 8 15
Duration ATT – month
 Median (range) 6 (1–9) 6 (1–9)
Severe adverse drug eventsa (ADE)– no. (%) 3 (14) 2 (10)
Last clinical assessment outcome – no. (%) n = 20 n = 6
 Resolved 14 (70) 0
 Improved 2 (10) 3 (50)
 No-change 4 (20) 3 (50)
  1. aMajor ADE = treatment discontinued (no.) - hepatotoxicity (1), rash (1), GI upset (2), severe fatigue (1)